.Nature Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA study, after a typical consequence of 11 months, individuals with metastatic stomach lumps that acquired biomarker-matched treatments based upon circulating growth DNA profiling showed a better scientific advantage than those obtaining incomparable therapy.